New drug cuts deaths among patients with no Covid antibodies

Oxford University trial reports cocktail of manmade antibodies reduces fatalities by a fifth

A new drug has been found to cut Covid deaths by a fifth among the sickest patients in hospital and may change official practice so that every patient with coronavirus will have an antibody test before they are admitted.

The Recovery trial based at Oxford University has found a third drug that can help Covid patients recover in hospital – but this one is the first to tackle the virus itself, rather than the inflammation that develops in the later stages of the disease.

Continue reading...

Ultra-thin film could one day turn regular glasses into night vision goggles, researchers say

Developed by Australian and European researchers, the film works by converting infrared light into light visible to the human eye

A transparent metallic film allowing a viewer to see in the dark could one day turn regular spectacles into night vision googles.

The ultra-thin film, made of a semiconductor called gallium arsenide, could also be used to develop compact and flexible infrared sensors, scientists say.

Continue reading...

The Covid Delta variant: how effective are the vaccines?

Analysis: what protection do they offer against infection, hospital admission and death?

As lockdown easing in England is delayed from 21 June to a possible date of 19 July amid concerns of a substantial wave of hospitalisations due to the Delta variant of coronavirus, we take a look at the latest data on the protection offered by vaccines.

Continue reading...

China set to administer 1bn Covid vaccine doses by end of this week

Cash incentives and gifts offered to fulfil target of vaccinating 40% of population by end of month

China is on track to administer 1bn vaccine doses by the end of this week, after bolstering production and distribution networks in an ambitious drive to vaccinate 40% of the population by this month.

Chinese authorities have been encouraging people to take the free and voluntary doses with cash incentives, gifts and colour-coded signage to laud or shame businesses depending on vaccination rates, as well as the promise of protection against Covid-19.

Continue reading...

Delaying England’s Covid reopening ‘could keep thousands out of hospital’

Research backs four-week delay on lifting restrictions to allow more people to get jabs

Ministers have been told that a four-week delay to easing all Covid restrictions would probably prevent thousands of hospitalisations, as Boris Johnson prepares to tell the English public they will have to wait up to another month for “freedom day”.

The government roadmap out of lockdown earmarks 21 June for the last remaining coronavirus restrictions to be lifted in England, but the prime minister is expected to announce on Monday that the timetable will be pushed back by two to four weeks amid a rapid rise in cases of the Delta variant first detected in India.

Continue reading...

Why are women more prone to long Covid?

While men over 50 tend to suffer the most acute symptoms of coronavirus, women who get long Covid outnumber men by as much as four to one

In June 2020, as the first reports of long Covid began to filter through the medical community, doctors attempting to grapple with this mysterious malaise began to notice an unusual trend. While acute cases of Covid-19 – particularly those hospitalised with the disease – tended to be mostly male and over 50, long Covid sufferers were, by contrast, both relatively young and overwhelmingly female.

Early reports of long Covid at a Paris hospital between May and July 2020 suggested that the average age was around 40, and women afflicted by the longer-term effects of Covid-19 outnumbered men by four to one.

Continue reading...

Drop Covid vaccine patent rules to save lives in poorest countries, Britain and Germany told

G7 summit hears move would slash the cost of jabs and accelerate rollout of programmes across the developing world

Britain and Germany were under intense pressure on Saturday to drop their resistance to proposals that would slash the cost of Covid-19 vaccines, following accusations that an agreement at the G7 summit to fund a billon doses will give the world’s poorest countries “crumbs from the table”.

Aid agencies said rules that protect drug patents from being illegally copied must be waived during the pandemic to accelerate the rollout of vaccines and save lives across the developing world.

Continue reading...

Should England open up on 21 June? The factors Johnson must consider

The prime minister has a host of problems to weigh up before deciding to remove all legal restrictions on social contact

The key issue is the extent to which infections of the Delta variant first detected in India will lead to hospitalisations and deaths. The problem is that it’s too early to say. Because of the lag between cases and admissions to hospital, many experts say a short delay could be a major benefit to understanding that relationship. “With the current knowledge about Delta, we can’t really predict the size of that wave,” said Anne Cori of Imperial College London’s modelling group. “Delaying the easing allows time to accumulate more evidence about the characteristics of Delta. And I hope in a few weeks, we would be in a better position to predict what the epidemic may look like in the next few weeks or months.”

Continue reading...

David Eagleman: ‘The working of the brain resembles drug dealers in Albuquerque’

The neuroscientist, broadcaster and author on the evolution of the brain, the mystery of consciousnesss, and why the next generation will be much smarter than us

David Eagleman, 50, is an American neuroscientist, bestselling author and presenter of the BBC series The Brain, as well as co-founder and chief executive officer of Neosensory, which develops devices for sensory substitution. His area of speciality is brain plasticity, and that is the subject of his new book, Livewired, which examines how experience refashions the brain, and shows that it is a much more adaptable organ than previously thought.

For the past half-century or more the brain has been spoken of in terms of a computer. What are the biggest flaws with that particular model?
It’s a very seductive comparison. But in fact, what we’re looking at is three pounds of material in our skulls that is essentially a very alien kind of material to us. It doesn’t write down memories, the way we think of a computer doing it. And it is capable of figuring out its own culture and identity and making leaps into the unknown. I’m here in Silicon Valley. Everything we talk about is hardware and software. But what’s happening in the brain is what I call livewire, where you have 86bn neurons, each with 10,000 connections, and they are constantly reconfiguring every second of your life. Even by the time you get to the end of this paragraph, you’ll be a slightly different person than you were at the beginning.

Continue reading...

Rapid Covid tests used in mass UK programme get scathing US report

Innova tests’ performance not proven and they should be returned to manufacturer or thrown in bin, says FDA

The US Food and Drug Agency (FDA) has raised significant concerns about the rapid Covid test on which the UK government has based its multibillion-pound mass testing programme.

In a scathing review, the US health agency suggested the performance of the test had not been established, presenting a risk to health, and that the tests should be thrown in the bin or returned to the California-based manufacturer Innova.

Continue reading...

Delta variant causes more than 90% of new Covid cases in UK

Variant first discovered in India is thought to spread more easily and be more resistant to vaccines

More than 90% of Covid cases in the UK are now down to the coronavirus Delta variant first discovered in India, data has revealed, as the total number of confirmed cases passed 42,000.

Also known as B.1.617.2, the Delta variant has been linked to a rise in Covid cases in the UK in the past weeks. It is believed to spread more easily than the Alpha variant, B.1.1.7, that was first detected in Kent, and is somewhat more resistant to Covid vaccines, particularly after just one dose. It may be also associated with a greater risk of hospitalisation.

Continue reading...

High risk of autumn Covid surge in Europe despite drop in infections, says WHO

Organisation urges governments to be cautious as societies open up and Delta variant advances

Covid-19 infections, hospitalisations and deaths are falling fast across Europe, but the risk of a deadly autumn resurgence remains high as societies open up and the more transmissible Delta variant advances, the World Health Organization (WHO) has said.

The warning came as new case numbers continued to plunge in most of the continent, falling in some areas to their lowest levels since August, and multiple governments, including France and Germany, relaxed restrictions further.

Continue reading...

Quantum leap for medical research as microscope zooms in on tiny structures

Australian scientists develop a microscope that works with 35% more clarity, raising hope for improvements in medical imaging

Australian researchers have developed a microscope that can image tiny biological structures that were previously not visible in what has been described as a significant step for quantum technology.

It is believed to be the first time that quantum technology has improved on existing light microscopes, which in future may lead to improvements in medical imaging and navigation systems.

Continue reading...

Covid distancing may have weakened children’s immune system, experts say

End of social distancing and mask-wearing could leave children vulnerable to common bugs

Scientists are concerned that measures to combat Covid-19 have weakened the immune systems of young children who have not been able to build up resistance to common bugs, leaving them vulnerable when mask-wearing and social distancing eventually end.

Contact with viral pathogens happens on a fairly regular basis and although it does not always lead to sickness, the exposure helps shore the immune system against the threat should the bugs be encountered again.

Continue reading...

FDA approves first new Alzheimer’s drug in almost 20 years

Usefulness of aducanumab is disputed but US approval will trigger push to make it available globally

A controversial new drug for Alzheimer’s disease, the first in nearly 20 years, was approved in the US on Monday, which will trigger pressure to make it available worldwide in spite of mixed evidence over its efficacy.

While doctors, patients and the organisations that support them are desperate for treatments that can slow mental deterioration, the usefulness of the new drug, aducanumab, is disputed by scientists. Two trials were stopped in March 2019 because the drugs appeared not to work. The manufacturer, Biogen, said the drugs were unlikely to improve people’s memory and thinking.

Continue reading...

Covid live: England reopening on 21 June could be delayed, say ministers; Israel begins vaccinating 12-16s

Latest updates: Delta variant is threat to timetable for England, says Matt Hancock; children aged from 12 in Israel eligible for jab after 55% of adults have had two doses

The US will donate 750,000 vaccine doses to Taiwan, a cross-party delegation of US senators said as they arrived in the country.

AFP report that the high-profile delegation and gift come as Taiwan accuses China of hampering its efforts to secure enough doses as part of Beijing’s ongoing campaign to keep the island isolated.

Morocco will reopen its airports to international traffic starting from 15 June to help the return of its nationals living abroad, the country’s foreign ministry said on Sunday.

Foreign nationals will also be allowed into the country if they have been vaccinated against Covid-19 or had a negative PCR test.

Continue reading...

Covid Delta variant ‘about 40% more transmissible’, says Matt Hancock

Under-30s to be offered jabs from next week but variant makes decision on easing rules in England ‘more difficult’

The new Delta variant of coronavirus appears to be about 40% more transmissible than the variant it has largely replaced, Matt Hancock has said, making government decisions about whether to ease restrictions in England on 21 June “more difficult”.

Saying that under-30s in England will be called to begin vaccinations from next week, the health secretary confirmed it was still possible the reopening programme could be delayed or some rules kept in place.

Continue reading...

HIV after Covid: Anthony Fauci and an army of researchers seek to regain momentum

In the summer of 1981, public health professionals faced a terrifying crisis. Their work helped shape victories against the current pandemic – but some fear hard-won ground is lost

As Anthony Fauci marks 40 years since HIV emerged, he regrets how the extraordinary disruptions that Covid-19 have wreaked upon society have hampered efforts to tackle the major pandemic that preceded it.

Related: 'Brand-new disease, no treatment, no cure': how Anthony Fauci's fight against Aids prepared him to tackle Covid-19

Continue reading...

Share vaccines or climate deal will fail, rich countries are told

Call for ‘solidarity’ in Covid fight as Boris Johnson calls on world leaders to help vaccinate global population by end of 2022

Progress on climate change could be scuppered by developing nations if they are not given equitable access to vaccines, Boris Johnson has been warned, as rich nations come under new pressure to donate more doses.

Figures compiled by the Observer show that the wealthiest nations, including the UK, have enough vaccines to inoculate their populations more than twice over.

Continue reading...

Drug may help more women survive hereditary breast cancer

International trials of olaparib were stopped early as benefits of ‘groundbreaking’ drug became clear

Women with hereditary breast cancer, triggered by the BRCA1 or BRCA2 genes, stand a better chance of survival following successful trials of a drug that cuts the likelihood of the cancer returning after treatment.

A major trial carried out by academic researchers to see whether olaparib can prevent recurrence was stopped early – after two-and-a-half years instead of the planned 10 years – when the benefits of the drug became clear.

Continue reading...